Orally Bioavailable Endochin-Like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts | Zendy

J. Stone Doggett | Zendy; Tracey L. Schultz | Zendy; Alyssa J. Miller | Zendy; Igor Bruzual | Zendy; Sovitj Pou | Zendy; Rolf W. Winter | Zendy; Rozalia A. Dodean | Zendy; Lev N. Zakharov | Zendy; Aaron Nilsen | Zendy; Michael K. Riscoe | Zendy; Vern B. Carruthers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Orally Bioavailable Endochin-Like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts

Author(s) -

J. Stone Doggett,

Tracey L. Schultz,

Alyssa J. Miller,

Igor Bruzual,

Sovitj Pou,

Rolf W. Winter,

Rozalia A. Dodean,

Lev N. Zakharov,

Aaron Nilsen,

Michael K. Riscoe,

Vern B. Carruthers

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00535-20

Subject(s) - toxoplasma gondii , toxoplasmosis , prodrug , in vitro , pharmacology , biology , adverse effect , quinolone , bioavailability , pyrimethamine , microbiology and biotechnology , immunology , virology , antibiotics , biochemistry , chloroquine , antibody , malaria

Toxoplasmosis is a potentially fatal infection for immunocompromised people and the developing fetus. Current medicines for toxoplasmosis have high rates of adverse effects that interfere with therapeutic and prophylactic regimens. Endochin-like quinolones (ELQs) are potent inhibitors ofToxoplasma gondii proliferationin vitro and in animal models of acute and latent infection. ELQ-316, in particular, was found to be effective orally against acute toxoplasmosis in mice and highly selective forT. gondii cytochromeb over human cytochromeb .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research